nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP3A4—bone cancer	0.451	1	CbGaD
Buprenorphine—ABCG2—Carboplatin—bone cancer	0.0733	0.231	CbGbCtD
Buprenorphine—ABCG2—Cisplatin—bone cancer	0.0626	0.197	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—bone cancer	0.042	0.132	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—bone cancer	0.0407	0.128	CbGbCtD
Buprenorphine—CYP2C9—Cisplatin—bone cancer	0.0233	0.0733	CbGbCtD
Buprenorphine—ABCB1—Cisplatin—bone cancer	0.0226	0.0711	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—bone cancer	0.0151	0.0477	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—bone cancer	0.0147	0.0462	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—bone cancer	0.0143	0.0449	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—bone cancer	0.00907	0.0286	CbGbCtD
Buprenorphine—Oxymorphone—CYP3A4—bone cancer	0.000781	0.578	CrCbGaD
Buprenorphine—Naloxone—CYP3A4—bone cancer	0.00057	0.422	CrCbGaD
Buprenorphine—Weight decreased—Epirubicin—bone cancer	0.000266	0.00212	CcSEcCtD
Buprenorphine—Angina pectoris—Doxorubicin—bone cancer	0.000265	0.00211	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Methotrexate—bone cancer	0.000265	0.00211	CcSEcCtD
Buprenorphine—Infestation NOS—Epirubicin—bone cancer	0.000262	0.00209	CcSEcCtD
Buprenorphine—Infestation—Epirubicin—bone cancer	0.000262	0.00209	CcSEcCtD
Buprenorphine—Bronchitis—Doxorubicin—bone cancer	0.000262	0.00208	CcSEcCtD
Buprenorphine—Body temperature increased—Cisplatin—bone cancer	0.000258	0.00205	CcSEcCtD
Buprenorphine—Urinary tract infection—Epirubicin—bone cancer	0.000255	0.00203	CcSEcCtD
Buprenorphine—Conjunctivitis—Epirubicin—bone cancer	0.000255	0.00203	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000253	0.00201	CcSEcCtD
Buprenorphine—Sweating—Epirubicin—bone cancer	0.000252	0.002	CcSEcCtD
Buprenorphine—Pharyngitis—Methotrexate—bone cancer	0.00025	0.00199	CcSEcCtD
Buprenorphine—Urinary tract disorder—Methotrexate—bone cancer	0.000249	0.00198	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Epirubicin—bone cancer	0.000248	0.00197	CcSEcCtD
Buprenorphine—Urethral disorder—Methotrexate—bone cancer	0.000247	0.00196	CcSEcCtD
Buprenorphine—Weight decreased—Doxorubicin—bone cancer	0.000246	0.00196	CcSEcCtD
Buprenorphine—Sinusitis—Epirubicin—bone cancer	0.000246	0.00196	CcSEcCtD
Buprenorphine—Infestation NOS—Doxorubicin—bone cancer	0.000243	0.00193	CcSEcCtD
Buprenorphine—Infestation—Doxorubicin—bone cancer	0.000243	0.00193	CcSEcCtD
Buprenorphine—Visual impairment—Methotrexate—bone cancer	0.000243	0.00193	CcSEcCtD
Buprenorphine—Hypersensitivity—Cisplatin—bone cancer	0.00024	0.00191	CcSEcCtD
Buprenorphine—Bradycardia—Epirubicin—bone cancer	0.00024	0.00191	CcSEcCtD
Buprenorphine—Rhinitis—Epirubicin—bone cancer	0.000236	0.00188	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—bone cancer	0.000236	0.00188	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—bone cancer	0.000236	0.00188	CcSEcCtD
Buprenorphine—Eye disorder—Methotrexate—bone cancer	0.000235	0.00187	CcSEcCtD
Buprenorphine—Tinnitus—Methotrexate—bone cancer	0.000235	0.00187	CcSEcCtD
Buprenorphine—Hypoaesthesia—Epirubicin—bone cancer	0.000234	0.00186	CcSEcCtD
Buprenorphine—Asthenia—Cisplatin—bone cancer	0.000234	0.00186	CcSEcCtD
Buprenorphine—Pharyngitis—Epirubicin—bone cancer	0.000234	0.00186	CcSEcCtD
Buprenorphine—Cardiac disorder—Methotrexate—bone cancer	0.000234	0.00186	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—bone cancer	0.000233	0.00185	CcSEcCtD
Buprenorphine—Urinary tract disorder—Epirubicin—bone cancer	0.000233	0.00185	CcSEcCtD
Buprenorphine—Oedema peripheral—Epirubicin—bone cancer	0.000232	0.00184	CcSEcCtD
Buprenorphine—Connective tissue disorder—Epirubicin—bone cancer	0.000232	0.00184	CcSEcCtD
Buprenorphine—Urethral disorder—Epirubicin—bone cancer	0.000231	0.00184	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—bone cancer	0.00023	0.00183	CcSEcCtD
Buprenorphine—Angiopathy—Methotrexate—bone cancer	0.000228	0.00182	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—bone cancer	0.000228	0.00181	CcSEcCtD
Buprenorphine—Immune system disorder—Methotrexate—bone cancer	0.000227	0.00181	CcSEcCtD
Buprenorphine—Visual impairment—Epirubicin—bone cancer	0.000227	0.0018	CcSEcCtD
Buprenorphine—Mediastinal disorder—Methotrexate—bone cancer	0.000227	0.0018	CcSEcCtD
Buprenorphine—Chills—Methotrexate—bone cancer	0.000226	0.0018	CcSEcCtD
Buprenorphine—Diarrhoea—Cisplatin—bone cancer	0.000223	0.00177	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—bone cancer	0.000222	0.00176	CcSEcCtD
Buprenorphine—Mental disorder—Methotrexate—bone cancer	0.000221	0.00175	CcSEcCtD
Buprenorphine—Eye disorder—Epirubicin—bone cancer	0.00022	0.00175	CcSEcCtD
Buprenorphine—Tinnitus—Epirubicin—bone cancer	0.00022	0.00175	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—bone cancer	0.000219	0.00174	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—bone cancer	0.000219	0.00174	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—bone cancer	0.000219	0.00174	CcSEcCtD
Buprenorphine—Flushing—Epirubicin—bone cancer	0.000219	0.00174	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—bone cancer	0.000219	0.00174	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—bone cancer	0.000217	0.00172	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—bone cancer	0.000216	0.00172	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—bone cancer	0.000215	0.00171	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—bone cancer	0.000215	0.00171	CcSEcCtD
Buprenorphine—Dysgeusia—Methotrexate—bone cancer	0.000215	0.00171	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—bone cancer	0.000214	0.0017	CcSEcCtD
Buprenorphine—Angiopathy—Epirubicin—bone cancer	0.000214	0.0017	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—bone cancer	0.000214	0.0017	CcSEcCtD
Buprenorphine—Immune system disorder—Epirubicin—bone cancer	0.000213	0.00169	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—bone cancer	0.000212	0.00169	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—bone cancer	0.000212	0.00169	CcSEcCtD
Buprenorphine—Chills—Epirubicin—bone cancer	0.000211	0.00168	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—bone cancer	0.00021	0.00167	CcSEcCtD
Buprenorphine—Vomiting—Cisplatin—bone cancer	0.000207	0.00165	CcSEcCtD
Buprenorphine—Vision blurred—Methotrexate—bone cancer	0.000207	0.00164	CcSEcCtD
Buprenorphine—Mental disorder—Epirubicin—bone cancer	0.000206	0.00164	CcSEcCtD
Buprenorphine—Rash—Cisplatin—bone cancer	0.000205	0.00163	CcSEcCtD
Buprenorphine—Dermatitis—Cisplatin—bone cancer	0.000205	0.00163	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—bone cancer	0.000205	0.00163	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—bone cancer	0.000205	0.00163	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—bone cancer	0.000204	0.00162	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—bone cancer	0.000203	0.00162	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—bone cancer	0.000203	0.00162	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—bone cancer	0.000202	0.00161	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—bone cancer	0.000202	0.00161	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—bone cancer	0.000202	0.00161	CcSEcCtD
Buprenorphine—Tension—Epirubicin—bone cancer	0.000201	0.0016	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—bone cancer	0.000201	0.0016	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—bone cancer	0.000199	0.00158	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—bone cancer	0.000198	0.00158	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—bone cancer	0.000198	0.00157	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—bone cancer	0.000198	0.00157	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—bone cancer	0.000197	0.00157	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—bone cancer	0.000197	0.00157	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—bone cancer	0.000197	0.00157	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—bone cancer	0.000196	0.00156	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—bone cancer	0.000196	0.00155	CcSEcCtD
Buprenorphine—Nausea—Cisplatin—bone cancer	0.000194	0.00154	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—bone cancer	0.000193	0.00154	CcSEcCtD
Buprenorphine—Cough—Methotrexate—bone cancer	0.000191	0.00152	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—bone cancer	0.000191	0.00152	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—bone cancer	0.00019	0.00151	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—bone cancer	0.00019	0.00151	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—bone cancer	0.00019	0.00151	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—bone cancer	0.00019	0.00151	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—bone cancer	0.000188	0.0015	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—bone cancer	0.000187	0.00149	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—bone cancer	0.000187	0.00148	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—bone cancer	0.000187	0.00148	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—bone cancer	0.000187	0.00148	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—bone cancer	0.000186	0.00148	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—bone cancer	0.000186	0.00148	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000185	0.00147	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—bone cancer	0.000185	0.00147	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—bone cancer	0.000184	0.00147	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—bone cancer	0.000184	0.00147	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—bone cancer	0.000184	0.00146	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—bone cancer	0.000184	0.00146	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—bone cancer	0.000184	0.00146	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—bone cancer	0.000182	0.00145	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—bone cancer	0.000181	0.00144	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—bone cancer	0.00018	0.00143	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—bone cancer	0.00018	0.00143	CcSEcCtD
Buprenorphine—Cough—Epirubicin—bone cancer	0.000179	0.00142	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—bone cancer	0.000179	0.00142	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—bone cancer	0.000179	0.00142	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—bone cancer	0.000178	0.00141	CcSEcCtD
Buprenorphine—Infection—Methotrexate—bone cancer	0.000178	0.00141	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—bone cancer	0.000177	0.00141	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—bone cancer	0.000176	0.0014	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—bone cancer	0.000175	0.00139	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—bone cancer	0.000175	0.00139	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—bone cancer	0.000175	0.00139	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—bone cancer	0.000175	0.00139	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—bone cancer	0.000174	0.00139	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—bone cancer	0.000174	0.00138	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—bone cancer	0.000174	0.00138	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000173	0.00138	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—bone cancer	0.000173	0.00137	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—bone cancer	0.000173	0.00137	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—bone cancer	0.000171	0.00136	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—bone cancer	0.000171	0.00136	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—bone cancer	0.00017	0.00136	CcSEcCtD
Buprenorphine—Anorexia—Methotrexate—bone cancer	0.00017	0.00136	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—bone cancer	0.00017	0.00135	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—bone cancer	0.000169	0.00134	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—bone cancer	0.000168	0.00133	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—bone cancer	0.000167	0.00133	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—bone cancer	0.000167	0.00133	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—bone cancer	0.000167	0.00133	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—bone cancer	0.000167	0.00133	CcSEcCtD
Buprenorphine—Infection—Epirubicin—bone cancer	0.000166	0.00132	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—bone cancer	0.000166	0.00132	CcSEcCtD
Buprenorphine—Shock—Epirubicin—bone cancer	0.000165	0.00131	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—bone cancer	0.000164	0.00131	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—bone cancer	0.000164	0.0013	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—bone cancer	0.000164	0.0013	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—bone cancer	0.000163	0.0013	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000163	0.0013	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—bone cancer	0.000163	0.00129	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—bone cancer	0.000162	0.00129	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—bone cancer	0.000162	0.00129	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—bone cancer	0.000162	0.00128	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—bone cancer	0.000162	0.00128	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—bone cancer	0.000162	0.00128	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—bone cancer	0.000161	0.00128	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—bone cancer	0.000161	0.00128	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00016	0.00128	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—bone cancer	0.00016	0.00127	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—bone cancer	0.00016	0.00127	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—bone cancer	0.000159	0.00127	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—bone cancer	0.000159	0.00126	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—bone cancer	0.000158	0.00126	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—bone cancer	0.000157	0.00125	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—bone cancer	0.000156	0.00124	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—bone cancer	0.000156	0.00124	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—bone cancer	0.000155	0.00124	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—bone cancer	0.000155	0.00123	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—bone cancer	0.000155	0.00123	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000154	0.00123	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—bone cancer	0.000154	0.00123	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—bone cancer	0.000154	0.00122	CcSEcCtD
Buprenorphine—Pain—Methotrexate—bone cancer	0.000153	0.00122	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000152	0.00121	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—bone cancer	0.000152	0.00121	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—bone cancer	0.000152	0.00121	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—bone cancer	0.000151	0.0012	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—bone cancer	0.000151	0.0012	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—bone cancer	0.00015	0.0012	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—bone cancer	0.00015	0.00119	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—bone cancer	0.00015	0.00119	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—bone cancer	0.000149	0.00119	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—bone cancer	0.000149	0.00118	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—bone cancer	0.000148	0.00117	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—bone cancer	0.000147	0.00117	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—bone cancer	0.000147	0.00117	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—bone cancer	0.000146	0.00116	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—bone cancer	0.000145	0.00116	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—bone cancer	0.000145	0.00115	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000144	0.00115	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—bone cancer	0.000144	0.00115	CcSEcCtD
Buprenorphine—Pain—Epirubicin—bone cancer	0.000143	0.00114	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—bone cancer	0.000143	0.00114	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—bone cancer	0.000142	0.00113	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—bone cancer	0.000141	0.00112	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—bone cancer	0.000141	0.00112	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000141	0.00112	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—bone cancer	0.00014	0.00111	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—bone cancer	0.000139	0.00111	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—bone cancer	0.000138	0.0011	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—bone cancer	0.000138	0.0011	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—bone cancer	0.000138	0.00109	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—bone cancer	0.000137	0.00109	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—bone cancer	0.000136	0.00108	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—bone cancer	0.000135	0.00107	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000134	0.00106	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—bone cancer	0.000134	0.00106	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—bone cancer	0.000133	0.00106	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—bone cancer	0.000132	0.00105	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—bone cancer	0.000132	0.00105	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—bone cancer	0.000132	0.00105	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—bone cancer	0.000132	0.00105	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—bone cancer	0.000132	0.00105	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—bone cancer	0.000128	0.00102	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—bone cancer	0.000128	0.00101	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000127	0.00101	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—bone cancer	0.000127	0.00101	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—bone cancer	0.000123	0.00098	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—bone cancer	0.000123	0.000978	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—bone cancer	0.000122	0.000973	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—bone cancer	0.000122	0.000973	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—bone cancer	0.000122	0.000973	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—bone cancer	0.00012	0.000955	CcSEcCtD
Buprenorphine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000119	0.00114	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—NDUFA12—bone cancer	0.000119	0.00114	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000119	0.00113	CbGpPWpGaD
Buprenorphine—Pruritus—Epirubicin—bone cancer	0.000118	0.000941	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—bone cancer	0.000118	0.00094	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—bone cancer	0.000115	0.00091	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—bone cancer	0.000114	0.000907	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—bone cancer	0.000114	0.000904	CcSEcCtD
Buprenorphine—Rash—Methotrexate—bone cancer	0.000113	0.000896	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—bone cancer	0.000113	0.000896	CcSEcCtD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000112	0.00107	CbGpPWpGaD
Buprenorphine—Headache—Methotrexate—bone cancer	0.000112	0.000891	CcSEcCtD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000111	0.00106	CbGpPWpGaD
Buprenorphine—Asthenia—Doxorubicin—bone cancer	0.000111	0.000883	CcSEcCtD
Buprenorphine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000111	0.00106	CbGpPWpGaD
Buprenorphine—Dizziness—Epirubicin—bone cancer	0.000111	0.00088	CcSEcCtD
Buprenorphine—OPRM1—GPCR ligand binding—SMO—bone cancer	0.00011	0.00105	CbGpPWpGaD
Buprenorphine—Pruritus—Doxorubicin—bone cancer	0.00011	0.000871	CcSEcCtD
Buprenorphine—OPRK1—Signaling by GPCR—GRM4—bone cancer	0.00011	0.00105	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—RGS1—bone cancer	0.00011	0.00105	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—GRM1—bone cancer	0.000108	0.00104	CbGpPWpGaD
Buprenorphine—Vomiting—Epirubicin—bone cancer	0.000106	0.000846	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—bone cancer	0.000106	0.000845	CcSEcCtD
Buprenorphine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000106	0.00101	CbGpPWpGaD
Buprenorphine—Diarrhoea—Doxorubicin—bone cancer	0.000106	0.000842	CcSEcCtD
Buprenorphine—OPRL1—Signaling Pathways—SMO—bone cancer	0.000106	0.00101	CbGpPWpGaD
Buprenorphine—Rash—Epirubicin—bone cancer	0.000106	0.000839	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—bone cancer	0.000105	0.000838	CcSEcCtD
Buprenorphine—Headache—Epirubicin—bone cancer	0.000105	0.000834	CcSEcCtD
Buprenorphine—OPRK1—GPCR downstream signaling—GRM1—bone cancer	0.000105	0.001	CbGpPWpGaD
Buprenorphine—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000104	0.000998	CbGpPWpGaD
Buprenorphine—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000103	0.000986	CbGpPWpGaD
Buprenorphine—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000103	0.000985	CbGpPWpGaD
Buprenorphine—Dizziness—Doxorubicin—bone cancer	0.000102	0.000814	CcSEcCtD
Buprenorphine—OPRM1—GPCR downstream signaling—RGS1—bone cancer	0.000102	0.000976	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—GRM4—bone cancer	0.000102	0.000976	CbGpPWpGaD
Buprenorphine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000102	0.000972	CbGpPWpGaD
Buprenorphine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000101	0.000967	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000101	0.000965	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—NDUFA12—bone cancer	0.000101	0.000964	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—NDUFA12—bone cancer	9.99e-05	0.000956	CbGpPWpGaD
Buprenorphine—Nausea—Epirubicin—bone cancer	9.94e-05	0.00079	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—bone cancer	9.85e-05	0.000783	CcSEcCtD
Buprenorphine—UGT1A9—Metabolism—NT5C3A—bone cancer	9.84e-05	0.000942	CbGpPWpGaD
Buprenorphine—Rash—Doxorubicin—bone cancer	9.76e-05	0.000776	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—bone cancer	9.76e-05	0.000776	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—bone cancer	9.7e-05	0.000771	CcSEcCtD
Buprenorphine—OPRL1—Signaling Pathways—GNA11—bone cancer	9.66e-05	0.000924	CbGpPWpGaD
Buprenorphine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	9.58e-05	0.000917	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—GRM1—bone cancer	9.5e-05	0.000909	CbGpPWpGaD
Buprenorphine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	9.31e-05	0.000891	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—RGS1—bone cancer	9.26e-05	0.000886	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—GRM4—bone cancer	9.26e-05	0.000886	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	9.23e-05	0.000884	CbGpPWpGaD
Buprenorphine—Nausea—Doxorubicin—bone cancer	9.2e-05	0.000731	CcSEcCtD
Buprenorphine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	9.18e-05	0.000879	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	9.18e-05	0.000878	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—NDUFA12—bone cancer	9.16e-05	0.000876	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—ATF1—bone cancer	8.98e-05	0.000859	CbGpPWpGaD
Buprenorphine—CYP2C8—Biological oxidations—GSTP1—bone cancer	8.92e-05	0.000854	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—GRM1—bone cancer	8.84e-05	0.000846	CbGpPWpGaD
Buprenorphine—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	8.8e-05	0.000842	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL3—bone cancer	8.76e-05	0.000838	CbGpPWpGaD
Buprenorphine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	8.64e-05	0.000827	CbGpPWpGaD
Buprenorphine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	8.57e-05	0.00082	CbGpPWpGaD
Buprenorphine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.49e-05	0.000812	CbGpPWpGaD
Buprenorphine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	8.45e-05	0.000808	CbGpPWpGaD
Buprenorphine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.37e-05	0.000801	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	8.36e-05	0.0008	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—NT5C3A—bone cancer	8.35e-05	0.000799	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	8.33e-05	0.000797	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—NT5C3A—bone cancer	8.28e-05	0.000792	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	8.24e-05	0.000789	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—GRM1—bone cancer	8.03e-05	0.000768	CbGpPWpGaD
Buprenorphine—CYP2C19—Biological oxidations—GSTP1—bone cancer	7.96e-05	0.000762	CbGpPWpGaD
Buprenorphine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	7.85e-05	0.000752	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	7.81e-05	0.000748	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—GNA11—bone cancer	7.69e-05	0.000736	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—SMO—bone cancer	7.63e-05	0.00073	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—NT5C3A—bone cancer	7.59e-05	0.000726	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TGFBR2—bone cancer	7.49e-05	0.000717	CbGpPWpGaD
Buprenorphine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7.39e-05	0.000707	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GRM4—bone cancer	7.38e-05	0.000706	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RGS1—bone cancer	7.38e-05	0.000706	CbGpPWpGaD
Buprenorphine—CYP2D6—Biological oxidations—GSTP1—bone cancer	7.33e-05	0.000701	CbGpPWpGaD
Buprenorphine—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.26e-05	0.000695	CbGpPWpGaD
Buprenorphine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	7.26e-05	0.000694	CbGpPWpGaD
Buprenorphine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	7.22e-05	0.000691	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NDUFA12—bone cancer	7.22e-05	0.000691	CbGpPWpGaD
Buprenorphine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.16e-05	0.000685	CbGpPWpGaD
Buprenorphine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	7.16e-05	0.000685	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IGF1R—bone cancer	7.05e-05	0.000674	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.99e-05	0.000669	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—GNA11—bone cancer	6.98e-05	0.000668	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—IL3—bone cancer	6.97e-05	0.000667	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.97e-05	0.000667	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—GNA11—bone cancer	6.74e-05	0.000645	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—SMO—bone cancer	6.69e-05	0.00064	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.55e-05	0.000626	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.55e-05	0.000626	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RGS1—bone cancer	6.47e-05	0.000619	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GRM4—bone cancer	6.47e-05	0.000619	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GRM1—bone cancer	6.4e-05	0.000612	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL3—bone cancer	6.33e-05	0.000606	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NDUFA12—bone cancer	6.25e-05	0.000598	CbGpPWpGaD
Buprenorphine—CYP1A2—Biological oxidations—GSTP1—bone cancer	6.21e-05	0.000594	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—GNA11—bone cancer	6.12e-05	0.000586	CbGpPWpGaD
Buprenorphine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	6.12e-05	0.000586	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—IL3—bone cancer	6.11e-05	0.000585	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.02e-05	0.000576	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NT5C3A—bone cancer	5.98e-05	0.000572	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—GNA11—bone cancer	5.7e-05	0.000545	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—SMO—bone cancer	5.66e-05	0.000541	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GRM1—bone cancer	5.61e-05	0.000537	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NDUFA12—bone cancer	5.58e-05	0.000534	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL3—bone cancer	5.55e-05	0.000531	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RGS1—bone cancer	5.47e-05	0.000523	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GRM4—bone cancer	5.47e-05	0.000523	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ENO2—bone cancer	5.45e-05	0.000522	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NDUFA12—bone cancer	5.45e-05	0.000521	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.18e-05	0.000496	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NT5C3A—bone cancer	5.18e-05	0.000496	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—GNA11—bone cancer	5.17e-05	0.000495	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—IL3—bone cancer	5.16e-05	0.000494	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NDUFA12—bone cancer	5.13e-05	0.000491	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—KIT—bone cancer	5.11e-05	0.000489	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NDUFA12—bone cancer	5.09e-05	0.000487	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—DHFR—bone cancer	5.06e-05	0.000484	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—BRAF—bone cancer	4.8e-05	0.00046	CbGpPWpGaD
Buprenorphine—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.79e-05	0.000458	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GRM1—bone cancer	4.74e-05	0.000454	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—GNA11—bone cancer	4.73e-05	0.000452	CbGpPWpGaD
Buprenorphine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.72e-05	0.000452	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL3—bone cancer	4.69e-05	0.000449	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—EGFR—bone cancer	4.66e-05	0.000446	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NT5C3A—bone cancer	4.63e-05	0.000443	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NT5C3A—bone cancer	4.51e-05	0.000432	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SMO—bone cancer	4.51e-05	0.000431	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NDUFA12—bone cancer	4.35e-05	0.000416	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ENO2—bone cancer	4.31e-05	0.000412	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CYP3A4—bone cancer	4.29e-05	0.00041	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NT5C3A—bone cancer	4.25e-05	0.000407	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NT5C3A—bone cancer	4.22e-05	0.000404	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GNA11—bone cancer	4.12e-05	0.000395	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MDM2—bone cancer	4.03e-05	0.000385	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—DHFR—bone cancer	4e-05	0.000383	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SMO—bone cancer	3.95e-05	0.000378	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.84e-05	0.000368	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ATF1—bone cancer	3.83e-05	0.000367	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL3—bone cancer	3.74e-05	0.000358	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GNA11—bone cancer	3.74e-05	0.000358	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.7e-05	0.000354	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—GSTP1—bone cancer	3.67e-05	0.000351	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ENO2—bone cancer	3.66e-05	0.00035	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ENO2—bone cancer	3.63e-05	0.000347	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GNA11—bone cancer	3.62e-05	0.000346	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NT5C3A—bone cancer	3.6e-05	0.000345	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—JUN—bone cancer	3.5e-05	0.000335	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MMP9—bone cancer	3.4e-05	0.000326	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—DHFR—bone cancer	3.39e-05	0.000325	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CYP3A4—bone cancer	3.39e-05	0.000324	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.37e-05	0.000323	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—DHFR—bone cancer	3.36e-05	0.000322	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ATF1—bone cancer	3.36e-05	0.000322	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NDUFA12—bone cancer	3.36e-05	0.000321	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SMO—bone cancer	3.34e-05	0.00032	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.34e-05	0.00032	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ENO2—bone cancer	3.32e-05	0.000318	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL3—bone cancer	3.28e-05	0.000314	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TGFBR2—bone cancer	3.2e-05	0.000306	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GNA11—bone cancer	3.17e-05	0.000303	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GNA11—bone cancer	3.14e-05	0.000301	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—DHFR—bone cancer	3.08e-05	0.000295	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GNA11—bone cancer	3.06e-05	0.000292	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IGF1R—bone cancer	3.01e-05	0.000288	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GSTP1—bone cancer	2.9e-05	0.000277	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GNA11—bone cancer	2.88e-05	0.000276	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CYP3A4—bone cancer	2.87e-05	0.000275	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CYP3A4—bone cancer	2.85e-05	0.000273	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ATF1—bone cancer	2.84e-05	0.000272	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TGFBR2—bone cancer	2.8e-05	0.000268	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NT5C3A—bone cancer	2.78e-05	0.000266	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL3—bone cancer	2.77e-05	0.000265	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—EGFR—bone cancer	2.75e-05	0.000263	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IGF1R—bone cancer	2.64e-05	0.000252	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.63e-05	0.000251	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ENO2—bone cancer	2.62e-05	0.000251	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CYP3A4—bone cancer	2.61e-05	0.00025	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GSTP1—bone cancer	2.46e-05	0.000235	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GSTP1—bone cancer	2.44e-05	0.000233	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—DHFR—bone cancer	2.43e-05	0.000233	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TGFBR2—bone cancer	2.37e-05	0.000227	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TP53—bone cancer	2.31e-05	0.000221	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GNA11—bone cancer	2.27e-05	0.000217	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ENO2—bone cancer	2.27e-05	0.000217	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GSTP1—bone cancer	2.23e-05	0.000214	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IGF1R—bone cancer	2.23e-05	0.000213	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.2e-05	0.000211	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KIT—bone cancer	2.18e-05	0.000209	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—DHFR—bone cancer	2.11e-05	0.000201	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CYP3A4—bone cancer	2.06e-05	0.000197	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—BRAF—bone cancer	2.05e-05	0.000196	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ENO2—bone cancer	2.03e-05	0.000194	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—EGFR—bone cancer	1.99e-05	0.00019	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ENO2—bone cancer	1.98e-05	0.000189	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GNA11—bone cancer	1.97e-05	0.000188	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KIT—bone cancer	1.91e-05	0.000183	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—bone cancer	1.9e-05	0.000182	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—DHFR—bone cancer	1.88e-05	0.00018	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ENO2—bone cancer	1.86e-05	0.000178	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ENO2—bone cancer	1.85e-05	0.000177	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—DHFR—bone cancer	1.83e-05	0.000176	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—BRAF—bone cancer	1.8e-05	0.000172	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CYP3A4—bone cancer	1.78e-05	0.000171	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.78e-05	0.00017	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSTP1—bone cancer	1.76e-05	0.000169	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GNA11—bone cancer	1.76e-05	0.000168	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—bone cancer	1.74e-05	0.000167	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—DHFR—bone cancer	1.73e-05	0.000165	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MDM2—bone cancer	1.72e-05	0.000164	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GNA11—bone cancer	1.71e-05	0.000164	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—DHFR—bone cancer	1.71e-05	0.000164	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KIT—bone cancer	1.62e-05	0.000155	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GNA11—bone cancer	1.62e-05	0.000155	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GNA11—bone cancer	1.6e-05	0.000153	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.59e-05	0.000152	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.58e-05	0.000152	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ENO2—bone cancer	1.58e-05	0.000151	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP3A4—bone cancer	1.55e-05	0.000149	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTP1—bone cancer	1.53e-05	0.000146	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—BRAF—bone cancer	1.52e-05	0.000145	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MDM2—bone cancer	1.51e-05	0.000144	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—bone cancer	1.5e-05	0.000144	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—JUN—bone cancer	1.49e-05	0.000143	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—bone cancer	1.47e-05	0.000141	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.46e-05	0.00014	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—DHFR—bone cancer	1.46e-05	0.00014	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—bone cancer	1.45e-05	0.000139	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.45e-05	0.000139	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.44e-05	0.000138	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GNA11—bone cancer	1.37e-05	0.000131	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTP1—bone cancer	1.36e-05	0.00013	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTP1—bone cancer	1.33e-05	0.000127	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—JUN—bone cancer	1.31e-05	0.000125	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—bone cancer	1.27e-05	0.000122	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—bone cancer	1.27e-05	0.000122	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MDM2—bone cancer	1.27e-05	0.000122	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—bone cancer	1.26e-05	0.000121	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTP1—bone cancer	1.25e-05	0.00012	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTP1—bone cancer	1.24e-05	0.000119	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.24e-05	0.000119	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.23e-05	0.000118	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO2—bone cancer	1.22e-05	0.000117	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—bone cancer	1.17e-05	0.000112	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—bone cancer	1.16e-05	0.000111	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—DHFR—bone cancer	1.13e-05	0.000108	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—JUN—bone cancer	1.11e-05	0.000106	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—bone cancer	1.08e-05	0.000103	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTP1—bone cancer	1.06e-05	0.000102	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GNA11—bone cancer	1.06e-05	0.000101	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—bone cancer	1.03e-05	9.85e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—bone cancer	9.86e-06	9.43e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—bone cancer	9.13e-06	8.73e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—bone cancer	8.7e-06	8.33e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—bone cancer	8.64e-06	8.27e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTP1—bone cancer	8.19e-06	7.84e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—bone cancer	7.91e-06	7.56e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—bone cancer	7.31e-06	6.99e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—bone cancer	7.06e-06	6.75e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—bone cancer	6.89e-06	6.59e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—bone cancer	6.49e-06	6.21e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—bone cancer	6.43e-06	6.16e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—bone cancer	5.5e-06	5.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—bone cancer	4.24e-06	4.06e-05	CbGpPWpGaD
